Sortiert nach Autor

Publikationen - sortiert nach Autor

• Dodd S, Bauer M, Carvalho A, Eyre H, Fava M, Kasper S, Kennedy S, Khoo J, Lopez Jaramillo C, Malhi G, McIntyre R, Mitchell P, Castro A, Ratheesh A, Severus E, Suppes T, Trivedi M, Thase M, Yatham L, Young A, Berk M (2021) A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? World J Biol Psychiatry, 22 (7): 483-494
  | Weblink |

• Komorowski A, Weidenauer A, Murgaš M, Sauerzopf U, Wadsak W, Mitterhauser M, Bauer M, Hacker M, Praschak-Rieder N, Kasper S, Lanzenberger R, Willeit M (2020) Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain Neuroimage, 223: 117270
  | Weblink |
• Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer B, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte H, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M (2020) On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study Transl Psychiat, 10 (2): 2
  | Weblink |

• Hienert M, Ritter P, Bauer M, Lanzenberger R, Kasper S (2019) Die klinische Anwendung von Milnacipran in Österreich und Deutschland Nervenheilkunde, 38 (04): 178-183
  | Weblink |

• Benedetti F, Avery D, Bauer M, Bunney W, Çaliyurt O, Camardese G, Colombo C, Dallaspezia S, Henriksen T, Kasper S, Kuriyama K, Lam R, Martiny K, Meesters Y, Mishima K, Schulte R, Suzuki M, Święcicki �, Uchiyama M, Veale D, Winkler D, Wu J, Kupeli N, Yoshiike T, Yu X (2018) Evidence for the Efficacy of Bright Light Therapy for Bipolar Depression Am J Psychiatry, 175 (9): 905-906
  | Weblink |

• Weidenauer A, Sauerzopf U, Bartova L, Bauer M, Praschak-Rieder N, Kasper S, Willeit M (2018) Sensibilisierung auf Amphetamine: Bedeutung für die Schizophrenie- und Suchtforschung Journal für Neurologie, Neurochirurgie und Psychiatrie, 19 (2): 66-der 71
  | Weblink |

• Litvan Z, Bauer M, Kasper S, Frey R (2017) Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia Int Psychogeriatr, 29 (07): 1223-1225
  | Weblink |

• Bauer M, Severus E, Möller H, Young A, (2017) Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines Int J Psychiatry Clin Pract, 21 (3): 166-176
  | Weblink |
• Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Praschak-Rieder N, Sitte H, Kasper S, Willeit M (2017) Making Sense of: Sensitization in Schizophrenia Int J Neuropsychopharmacol, 20 (1): 1-10
  | Weblink |

• Bauer M, Karch R, Zeitlinger M, Liu J, Koepp M, Asselin M, Sisodiya S, Hainfellner J, Wadsak W, Mitterhauser M, Muller M, Pataraia E, Langer O (2014) In vivo P-glycoprotein function before and after epilepsy surgery Neurology,
• Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Müller M, Langer O (2014) Using Positron Emission Tomography to Study Transporter-Mediated Drug–Drug Interactions in Tissues Clin Pharmacol Ther, 96 (2): 206-213

• Bauer M, Zeitlinger M, Todorut D, Böhmdorfer M, Müller M, Langer O, Jäger W (2013) Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects Pharmacology, 91 (1-2): 12-19
• Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, Mitterhauser M, Jager W, Haslacher H, Muller M, Langer O (2013) Interaction of 11C-Tariquidar and 11C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood-Brain Barrier J Nucl Med, 54 (8): 1181-1187

• Pfabigan D, Alexopoulos J, Bauer H, Lamm C, Sailer U (2011) All about the Money ? External Performance Monitoring is Affected by Monetary, but Not by Socially Conveyed Feedback Cues in More Antisocial Individuals Front Hum Neurosci, 5
• Wagner C, Simpson M, Zeitlinger M, Bauer M, Karch R, Abrahim A, Feurstein T, Schütz M, Kletter K, Müller M, Lappin G, Langer O (2011) A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil Clin Pharmacokinet, 50 (2): 111-120
• Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jäger W, Böhmdorfer M, Wadsak W, Mitterhauser M, Bankstahl J, Löscher W, Koepp M, Kuntner C, Müller M, Langer O (2011) Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data Clin Pharmacol Ther, 91 (2): 227-233

• Pfabigan D, Alexopoulos J, Bauer H, Sailer U (2010) Manipulation of feedback expectancy and valence induces negative and positive reward prediction error signals manifest in event-related brain potentials Psychophysiology, 48 (5): 656-664
• Bauer M, Bliesath H, Leuratti C, Lackner E, Dieterle W, Müller M, Brunner M (2010) Disposition and Metabolism of Ralfinamide, a Novel Na-Channel Blocker, in Healthy Male Volunteers Pharmacology, 86 (5-6): 297-305

• Bauer M, Karch R, Neumann F, Abrahim A, Wagner C, Kletter K, Müller M, Zeitlinger M, Langer O (2009) Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET Eur J Clin Pharmacol, 65 (9): 941-946
• Wagner C, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, Kletter K, Loscher W, Muller M, Zeitlinger M, Langer O (2009) A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood-Brain Barrier with (R)-11C-Verapamil and PET J Nucl Med, 50 (12): 1954-1961
• Bauer M, Karch R, Neumann F, Wagner C, Kletter K, Müller M, Löscher W, Zeitlinger M, Langer O (2009) Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood–brain barrier J Cereb Blood Flow Metab, 30 (3): 510-515

• Steiner I, Errhalt P, Kubesch K, Hubner M, Holy M, Bauer M, Müller M, Hinterberger S, Widmann R, Mascher D, Freissmuth M, Kneussl M (2008) Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers Naunyn Schmiedebergs Arch Pharmacol, 378 (3): 323-333

• Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp M, Abrahim A, Luurtsema G, Brunner M, Sunder-Plassmann R, Zimprich F, Joukhadar C, Gentzsch S, Dudczak R, Kletter K, Müller M, Baumgartner C (2007) Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R -[ 11 C]verapamil Epilepsia, 48 (9): 1774-1784

• BAUER M, LANGER O, DALBIANCO P, KARCH R, BRUNNER M, ABRAHIM A, LANZENBERGER R, HOFMANN A, JOUKHADAR C, CARMINATI P (2006) A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease Clin Pharmacol Ther, 80 (3): 216-227